Close

We are using cookies to give you the best experience on our site. Cookies are files stored in your browser and are used by most websites to help personalise your web experience.

By continuing to use our website without changing the settings, you are agreeing to our use of cookies.

Find out more
For more information, go to www.arthritisresearchuk.org

Strategy development and priority setting

Our principal goal is to devise a strategy for clinical studies in SpA which will result in well designed clinical trials which Arthritis Research UK will wish to fund and which can be delivered with the help of the infrastructure put in place by the UK government in the form of clinical research networks.

As part of Arthritis Research UK's new strategy for funding clinical trials, Clinical Studies Groups (CSGs) have been set up in seven major clinical areas, one of which is spondyloarthritis (SpA) – i.e. ankylosing spondylitis, psoriatic arthritis, the arthritis of inflammatory bowel disease, reactive arthritis and undifferentiated spondyloarthritis.

No decisions on whether other forms of arthritis (e.g. SAPHO) might be within our remit have been made and the CSG is open to suggestions on this.

  • Core values for the CSG 
  • Transparency and openness
  • Inclusiveness
  • Goal–oriented – we must facilitate the development, in a useful time frame, of robust clinical trial proposals which command wide support in the SpA community and will be very fundable by Arthritis Research UK  

For more information please read the Spondyloarthopathies CSG strategy (PDF 104 KB)

For more information, go to www.arthritisresearchuk.org.
Arthritis Research UK fund research into the cause, treatment and cure of arthritis. You can support Arthritis Research UK by volunteering, donating or visiting our shops.